Oxygen-generating cryogels

Patent metadata

Field	Value
Publication number	US-12303618-B2
Application number	US-201917266351-A
Country	US
Kind code	B2
Filing date	Aug 8, 2019
Priority date	Aug 8, 2018
Publication date	May 20, 2025
Grant date	May 20, 2025

Abstract

Disclosed are nanocomposite oxygen-generating cryogels and their uses in reducing hypoxia in a biological tissue, such as a tumor. Methods of treating cancer with the disclosed cryogels are also provided.

First claim

The invention claimed is:

1. A method of reducing hypoxia in a biological tissue, comprising administering to the biological tissue an oxygen-generating cryogel, wherein the administration is by injection, catheter, or surgery; and the cryogel comprises:
i) a lyoprotectant;
ii) a peroxide, an oxide or a percarbonate;
iii) a catalase, wherein the catalase is acrylate-PEG-catalase; and
iv) polymerized hyaluronic acid.

2. The method of claim 1 , wherein the cryogel further comprises G4RDGSP; wherein the G4RDGSP is conjugated to the cryogel.

3. The method of claim 2 , wherein the polymerized hyaluronic acid is comprised by polymerized hyaluronic acid glycidyl methacrylate, the G4RDGSP is comprised by acrylate-PEG-G4RDGSP, and the peroxide, oxide or percarbonate is CaO 2 .

4. The method of claim 1 , wherein the lyoprotectant is selected from sucrose, trehalose, and mannitol.

5. The method of claim 1 , wherein the cryogel further comprises one or more checkpoint inhibitors selected from one or more adenosine receptor antagonists for A2a, A2b or A3 receptors, anti-CTLA4, anti-CD73, anti-PD1, and anti-PD-L1.

6. The method of claim 1 , wherein the cryogel has a mean size of 1 μm to 10 cm, 10 μm to 10 mm, 50 μm to 2 mm, 1 μm to 5 mm, 1 μm to 2 mm, or 5 μm to 500 μm.

7. The method of claim 1 , wherein the hypoxia is reduced such that oxygen tissue tension is higher than 5% oxygen.

8. The method of claim 1 , wherein the cryogel releases oxygen for at least about 4 hours, at least about 16 hours, at least about 24 hours, at least about 48 hours, or at least about 96 hours.

9. The method of claim 1 , wherein the cryogel increases oxygen concentration in the biological tissue to physioxic or normoxic levels.

10. The method of claim 1 , wherein hypoxia-induced immunosuppression of one or more of T cells, B cells, and myeloid cells is reduced or reversed compared to immunosuppression levels in hypoxic biological tissue.

11. The method of claim 1 , wherein extracellular adenosine concentration in hypoxic biological tissue decreases to levels present in normoxic biological tissue.

12. The method of claim 1 , wherein the biological tissue is a solid tumor selected from melanoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, pancreatic cancer, glioblastoma, ovarian cancer, colon cancer, sarcoma, nasopharyngeal cancer, head and neck cancer, and lymphoma.

13. The method of claim 1 , wherein the peroxide, oxide or percarbonate is calcium peroxide or magnesium peroxide.

14. The method of claim 1 , wherein the peroxide, oxide or percarbonate is encapsulated H 2 O 2 /polyvinylpyrrolidone or hydrogen peroxide.

15. The method of claim 1 , wherein the peroxide, oxide or percarbonate is sodium percarbonate.

16. The method of claim 1 , wherein the peroxide, oxide or percarbonate is zinc oxide or manganese dioxide.

17. The method of claim 3 , wherein the lyoprotectant is selected from sucrose, trehalose, and mannitol.

18. The method of claim 2 , wherein the G4RDGSP is comprised by acrylate-PEG-G4RDGSP.

19. The method of claim 1 , wherein the polymerized hyaluronic acid is comprised by polymerized hyaluronic acid glycidyl methacrylate.

20. The method of claim 1 , wherein the cryogel further comprises one or more adenosine receptor antagonists selected from the group consisting of ZM241385, 1,7-methylxantine, theophylline, theobromine, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine], and (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione.

21. The method of claim 3 , wherein the cryogel further comprises
(i) one or more checkpoint inhibitors selected from one or more adenosine receptor antagonists for A2a, A2b or A3 receptors, anti-CTLA4, anti-CD73, anti-PD1, and anti-PD-L1; or
(ii) one or more adenosine receptor antagonists selected from the group consisting of ZM241385, 1,7-methylxantine, theophylline, theobromine, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine], and (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione.

Assignees

• Univ Northeastern

Inventors

• Memic Adnan
• Bencherif Sidi A
• Sitkovsky Michail
• Colombani Thibault
• Hatfield Stephen

Classifications

• A61L2300/416

  Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus · CPC title

• A61L2300/254

  Enzymes, proenzymes · CPC title

• A61L2300/11

  Peroxy compounds, peroxides, e.g. hydrogen peroxide · CPC title

• A61L27/52

  Hydrogels or hydrocolloids · CPC title

• A61L27/20

  Polysaccharides · CPC title